Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.

La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients

La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients

The company intends to submit a marketing application for LJPC-501 to the FDA in the second half of the year, pending the outcome of a meeting with regulators.

Trevena Makes Case for Better Post-Surgical Opioid with New Study Data

Trevena Makes Case for Better Post-Surgical Opioid with New Study Data

Trevena intends to submit the new painkiller, known as oliceridine, for marketing approval with the U.S. Food and Drug Administration in the fourth quarter, the company said.

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.